lillydirect self pay tirzepatide Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity New Zepbound TV Commercial Highlights

CONTRAINDICATIONS AND INTERACTIONS

Full in-clinic treatment options IVs Peptides Stem Cells HBOT Cryo Shockwave PEMF + more to compliment your program Mail-in kit

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, can be reached at [email protected]

The following antibodies were used: H3K4me3 (Millipore 17-614) 1:2000, H3K9me3 (Abcam ab8898) 1:1000, H3K27me3 (Millipore 17-622) 1:2000, H3 (Cell Signaling Tech 4499 monoclonal, clone# D1H2) 1:2000, JARID1A (Cell Signaling Tech 3876 monoclonal, clone# D28B10) 1:1000, JARID1B (Cell Signaling Tech 3273) 1:1000, JARID1C (Cell Signaling Tech 5361 monoclonal, clone# D29B9) 1:1000, and -actin (Sigma A1978 monoclonal, clone# AC15) 1:10,000

public health 18 (3), 989